{"filing":{"accession_number":"0001599298-26-000076","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-02","primary_document":"smmt-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/smmt-20260902.htm"},"events":[{"id":31520,"run_id":28926,"accession_number":"0001599298-26-000076","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Summit disclosed positive overall survival results from its partner Akeso's Phase III HARMONi-2 study of ivonescimab, a key investigational drug in Summit's pipeline. While this is clinical trial data rather than a formal earnings release or regulatory approval, the statistically significant OS benefit in a Phase III study for a lead oncology candidate is material to investors' assessment of the company's development prospects and pipeline value. The disclosure emphasizes Summit's ongoing HARMONi-7 trial and broader clinical program, making this an operational/clinical milestone rather than a financial or governance event.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34439,"accession_number":"0001599298-26-000076","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit disclosed positive overall survival results from its partner Akeso's Phase III HARMONi-2 study of ivonescimab, a key investigational drug in Summit's pipeline. While this is clinical trial data rather than a formal earnings release or regulatory approval, the statistically significant OS benefit in a Phase III study for a lead oncology candidate is material to investors' assessment of the company's development prospects and pipeline value. The disclosure emphasizes Summit's ongoing HARMONi-7 trial and broader clinical program, making this an operational/clinical milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T13:23:38.207215+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34439,"accession_number":"0001599298-26-000076","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit disclosed positive overall survival results from its partner Akeso's Phase III HARMONi-2 study of ivonescimab, a key investigational drug in Summit's pipeline. While this is clinical trial data rather than a formal earnings release or regulatory approval, the statistically significant OS benefit in a Phase III study for a lead oncology candidate is material to investors' assessment of the company's development prospects and pipeline value. The disclosure emphasizes Summit's ongoing HARMONi-7 trial and broader clinical program, making this an operational/clinical milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T13:23:38.207215+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-03"}]}